Piperine, a trans-trans isomer of 1-piperoyl-piperidine, in combination with ciprofloxacin markedly reduced the MICs and mutation prevention concentration of ciprofloxacin for Staphylococcus aureus, including methicillin-resistant S. aureus. The enhanced accumulation and decreased efflux of ethidium bromide in the wild-type and mutant (CIP r -1) strains in the presence of piperine suggest its involvement in the inhibition of bacterial efflux pumps.Ciprofloxacin, the most frequently used fluoroquinolone, is less effective against gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis (8). Fluoroquinolones inhibit DNA synthesis by inhibiting the closely related enzymes gyrase and topoisomerase IV. The resistance to this class of antibiotics is caused by changes in the genes coding for DNA gyrase (gyrA or gyrB) or for topoisomerase IV (parC or parE) (11). The regions in which these mutations occur are termed quinolone resistance-determining regions (16,17). However multidrug efflux transporters also play a major role in contributing to the resistance of gram-positive organisms to fluoroquinolones by actively extruding fluoroquinolones and multiple other drugs from cells (4, 12, 21).Piperine, the major plant alkaloid present in black pepper (Piper nigrum) and long pepper (Piper longum), is reported to have bioavailability-enhancing activity for some nutritional substances and for some drugs (1, 3). Piperine has previously been shown to inhibit several cytochrome P450-mediated pathways and phase II reactions in animal models (2,19). It has also been proven to be an inhibitor of human P-glycoprotein (5). In this report, we describe for the first time the potentiating effect of piperine with ciprofloxacin in in vitro combination studies against S. aureus and its suggestive role as an efflux pump inhibitor.S. aureus ATCC 29213 was obtained from the American Type Culture Collection (Manassas, Va.). Methicillin-resistant S. aureus (MRSA) 33, MRSA 450, and MRSA 15187 were obtained as a kind gift from Ranbaxy Research Laboratories (New Delhi, India). Ciprofloxacin powder was obtained from Cadila Pharmaceuticals, Gujarat, India. Piperine of 99% purity was provided by the Pharmacology Division, Regional Research Laboratory, Jammu Tawi, India. Reserpine was obtained from Sigma Aldrich, St. Louis, Mo. Mueller-Hinton broth (Becton Dickinson, Cockeysville, Md.) supplemented with calcium (25 mg/liter) and magnesium (12.5 mg/liter) was used for all susceptibility and killing curve experiments. MuellerHinton agar (Becton Dickinson) was used for mutation studies. Trypticase soy agar (Becton Dickinson) was used for colony counts.In vitro combination studies. Combination studies were performed by a broth checkerboard method (9). The final concentrations ranged from 0.03 g/ml to 64 g/ml for ciprofloxacin and from 0.8 g/ml to 50 g/ml for piperine. The final bacterial inoculum in each well was 5 ϫ 10 5 CFU/ml. The plates were incubated at 37°C for 24 h. Piperine did not show any antiba...
A newly identified class of compounds derived from a natural amide, piperine, is more potent than the parent molecule in potentiating the activity of ciprofloxacin through the inhibition of the NorA efflux pump. These molecules may prove useful in augmenting the antibacterial activities of fluoroquinolones in a clinical setting.
Piperine, a trans-trans-isomer of 1-piperoyl-piperidine, was tested in combination with mupirocin for antimicrobial activity against Staphylococcus aureus strains including meticillin-resistant S. aureus. The combination markedly reduced the MIC of mupirocin and also lowered the mutation frequency. Enhanced accumulation and efflux of ethidium bromide from wild-type and mutant (Mup r -1) strains in the presence of piperine indicated that inhibition of efflux could be a possible mechanism of potentiation of mupirocin activity by piperine. The combination of piperine with mupirocin in a dermal infection model of mice showed better in vivo efficacy when compared with the commercially available formulation of 2 % mupirocin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.